Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25742569 | 1.00 | PLAU (0.41) | PLAUS1PR1S1PR3KMT2AMEN1 | |
| SCHEMBL21598707 | 0.81 | PLAU (0.43) | PLAUS1PR1S1PR3KMT2AMEN1 | |
| SCHEMBL23608765 | 0.77 | PLAU (0.40) | PLAUS1PR1S1PR3KMT2AMEN1 | |
| SCHEMBL28634201 | 0.77 | PLAU (0.33) | PLAUS1PR1S1PR3KMT2AMEN1 | |
| SCHEMBL16139588 | 0.77 | S1PR1 (0.42) | PLAUS1PR1S1PR3KMT2AMEN1 | |
| SCHEMBL25742429 | 0.75 | PLAU (0.41) | PLAUS1PR1S1PR3KMT2AMEN1 | |
| SCHEMBL29818584 | 0.75 | PLAU (0.41) | PLAUS1PR1S1PR3KMT2AMEN1 | |
| SCHEMBL10179832 | 0.74 | S1PR1 (0.34) | PLAUS1PR1S1PR3MAPK1 | |
| SCHEMBL13119982 | 0.74 | S1PR1 (0.47) | PLAUS1PR1S1PR3KMT2AMEN1 | |
| SCHEMBL17979053 | 0.73 | PLAU (0.42) | PLAUS1PR1S1PR3KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120442-A | Tricyclic compounds useful for treating cancer, autoimmune disorders, and inflammatory disorders | 薛定谔公司 | 2023-11-24 | — | — | CN | disclosed |